CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

Lower research spending narrowed the quarterly loss, while grant revenue ended following completion of the RewinD-LB trial.

Rhea-AI Summary

CervoMed (CRVO) reported a narrower third-quarter 2026 net loss of approximately $5.9 million and outlined upcoming neflamapimod clinical milestones. The loss compared with approximately $7.7 million a year earlier. Cash, cash equivalents and marketable securities totaled approximately $19.6 million at September 30, 2026; the company expects funding to last through the third quarter of 2027.

The FDA removed a prior drug exposure limit, supporting future trials using 100mg twice daily. Preliminary 12-week data in nonfluent variant primary progressive aphasia showed reduced mean levels of a neuronal-damage biomarker. CervoMed expects 24-week biomarker data in November 2026 and full topline results in the second quarter of 2027. Stroke-trial enrollment reached 45 patients, with topline data expected by year-end 2026. The company is seeking a partnership to advance neflamapimod into Phase 3 for dementia with Lewy bodies.

13 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 5 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointNet loss narrowed to approximately $5.9 million in third-quarter 2026 from approximately $7.7 million a year earlier.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Cash runway is expected through third-quarter 2027 under CervoMed’s current operating plan.
• Moderate pointFDA removal of the prior exposure limit supports 100mg twice-daily dosing in future neflamapimod trials.
• Minor pointR&D expenses fell to approximately $3.7 million in third-quarter 2026 from approximately $6.0 million a year earlier.
• Minor pointInnovation Passport designation awarded in August 2026 provides access to the UK Innovative Licensing and Access Pathway.

8 minor points

• Minor pointPreliminary 12-week Phase 2a results in nonfluent variant primary progressive aphasia showed reduced mean plasma neurofilament light chain.
• Minor pointDLB extension-phase biomarker findings published in Cells showed modulation of neuroinflammatory processes implicated in neuronal damage and cognitive decline.
• Minor pointRESTORE enrollment completed with 45 patients recovering from acute ischemic stroke.
• Minor point. Forward-looking: it has not happened yet and may not happen.RESTORE topline data are expected by the end of 2026.
• Minor point. Forward-looking: it has not happened yet and may not happen.24-week aphasia biomarker data are expected at CTAD in mid-November 2026.
• Minor point. Forward-looking: it has not happened yet and may not happen.Initial 24-week aphasia clinical data and additional biomarker data are expected in March 2027.
• Minor point. Forward-looking: it has not happened yet and may not happen.Full aphasia trial topline data are expected in the second quarter of 2027.
• Minor point. Forward-looking: it has not happened yet and may not happen.First-patient dosing in EXPERTS-ALS is expected in the first quarter of 2027.

Negative

• Moderate pointNo further funding is available or expected under the prior $21.3 million National Institute on Aging grant. 99% of market cap
• Moderate point. Forward-looking: it has not happened yet and may not happen.DLB Phase 3 advancement remains a partnership objective, with CervoMed continuing to evaluate financing alternatives.
• Minor pointCash, cash equivalents and marketable securities declined to approximately $19.6 million from $20.9 million at December 31, 2025.
• Minor pointGrant revenue was zero in third-quarter 2026, versus approximately $0.3 million a year earlier.
• Minor pointG&A expenses increased to approximately $2.4 million in third-quarter 2026 from approximately $2.3 million a year earlier.

Key Figures

Cash and marketable securities: $19.6 million Cash runway: Through the third quarter of 2027 Grant revenue: $0 +5 more

Cash and marketable securities

$19.6 million

As of September 30, 2026; compared with $20.9 million as of December 31, 2025

Cash runway

Through the third quarter of 2027

Based on the company's current operating plan and September 30, 2026 cash position

Grant revenue

$0

Three months ended September 30, 2026; compared with approximately $0.3 million in 2025

R&D expenses

Approximately $3.7 million

Three months ended September 30, 2026; compared with approximately $6.0 million in 2025

G&A expenses

Approximately $2.4 million

Three months ended September 30, 2026; compared with approximately $2.3 million in 2025

Net loss

Approximately $5.9 million

Three months ended September 30, 2026; compared with approximately $7.7 million in 2025

Previously awarded grant

$21.3 million

No further funding under the grant was available or expected

RESTORE enrollment

45 patients

Enrollment completed in the Phase 2a trial evaluating recovery after acute ischemic stroke

Previous Earnings Reports

1 past event · Latest: Nov 10

Same Type 1 event

1. Nov 10

   Quarterly earnings

   24h Move

   -0.3%

   Reported Q3 net loss of $7.7M, the year-over-year comparator cited in this release.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pharmacokinetic, neurofilament light chain, placebo-controlled, nonfluent variant primary progressive aphasia

4 terms

pharmacokinetic medical

"announced the pharmacokinetic properties of a 50mg oral tablet formulation"

Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

neurofilament light chain medical

"a reduction in mean plasma levels of neurofilament light chain"

Neurofilament light chain is a protein released into cerebrospinal fluid and blood when nerve cells are damaged, acting like a measurable “leak” that signals injury to the brain or spinal cord. For investors, it matters because rising or falling levels can serve as an objective readout in clinical trials and disease monitoring, helping assess whether a drug or therapy is slowing nerve damage and reducing development or commercial risk.

placebo-controlled medical

"The placebo-controlled results of the Phase 2b RewinD-LB trial"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

nonfluent variant primary progressive aphasia medical

"patients with nonfluent variant primary progressive aphasia (nfvPPA)"

A progressive neurological disorder that primarily impairs the ability to produce speech and form grammar while other thinking skills decline more slowly; it is one subtype of primary progressive aphasia caused by ongoing brain degeneration. For investors, it matters because diagnosis rates, disease progression, and clinical endpoints influence the size of patient populations, the design and length of clinical trials, regulatory review, and potential market demand for therapies — like a slowly failing engine that needs targeted repairs rather than a one-time fix.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Presentation and publication of clinical and biomarker data, regulatory developments, 
and 100mg BID dosing regimen support advancement of the neflamapimod clinical development program in dementia with Lewy bodies

Rapidly advancing neflamapimod for the treatment of nonfluent variant primary progressive aphasia; 24-week biomarker data selected for presentation at the 19^th Annual Clinical Trials on Alzheimer’s Disease Conference (CTAD 2026)

BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today reported financial results for the third quarter ended September 30, 2026, and provided corporate updates.

“The Company believes that the neflamapimod clinical development program has been significantly de-risked through the presentation and publication of compelling, supportive datasets throughout this year and the ability to advance the 100mg BID dosing regimen, strengthening its position as a potential therapeutic for dementia with Lewy bodies and other devastating neurodegenerative disorders,” stated John Alam, MD, Chief Executive Officer of CervoMed.

“As we look ahead to the remainder of the year and into 2027, we believe neflamapimod is well-positioned to succeed in the clinic, drive stockholder value, and ultimately, if approved, bring a transformative therapy to a market with massive, unmet medical needs. We have several upcoming milestones that we are working toward, including 24-week biomarker data from our Phase 2 clinical trial in patients with nonfluent variant primary progressive aphasia at CTAD 2026, Phase 2a data in recovery after stroke, and the commencement of dosing in ALS,” concluded Dr. Alam.

Third Quarter 2026 and Recent Program Highlights

Dementia with Lewy Bodies (DLB)

• In July 2026, at the Alzheimer’s Association International Conference (AAIC), CervoMed reported new clinical, plasma biomarker, and MRI imaging data across five data presentations that highlighted insights into neflamapimod’s treatment effects in DLB. The data provide further supportive evidence that neflamapimod has the potential to address the underlying cause of DLB. The AAIC data presentations can be accessed here.
  
  
• In August 2026, neflamapimod was awarded Innovation Passport designation under the United Kingdom Innovative Licensing and Access Pathway (ILAP) for the treatment of DLB. The Innovation Passport is designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines.
  
  
• In September 2026, CervoMed announced the pharmacokinetic properties of a 50mg oral tablet formulation of neflamapimod that will be utilized in CervoMed’s future clinical studies, as well as the United States (US) Food and Drug Administration’s (FDA) removal of a prior neflamapimod drug exposure limit for future clinical trials. These advances support the use of a 100mg BID dosing regimen in CervoMed's future clinical trials, which the Company believes is the optimal dosing regimen and expects to achieve target trough plasma drug concentrations in nearly all patients.
  
  
• In October 2026, CervoMed announced the publication of two peer-reviewed articles supporting neflamapimod as a potential treatment for DLB. The placebo-controlled results of the Phase 2b RewinD-LB trial were published in Alzheimer’s Research & Therapy and translational findings, which included extension phase biomarker data from the RewinD-LB trial showing that neflamapimod modulates key neuroinflammatory processes implicated in neuronal damage and cognitive decline in DLB, were published in Cells.
  
  

Frontotemporal Dementia (FTD)

• In October 2026, CervoMed presented initial 12-week biomarker results from its ongoing Phase 2a trial evaluating neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA), a type of FTD, in a late-breaking oral session at the 15^th International Conference on Frontotemporal Dementias. These preliminary data demonstrated a reduction in mean plasma levels of neurofilament light chain, a key biomarker of neuronal damage and degeneration. 24-week biomarker data from this Phase 2a trial have been selected for presentation at CTAD 2026, taking place November 16-19, 2026 in Boston, Massachusetts.
  
  

Recovery After Stroke (RAS)

• CervoMed recently completed enrollment of 45 patients in the Phase 2a RESTORE trial evaluating neflamapimod in patients recovering from acute ischemic stroke.
  
  

Anticipated Milestones

CervoMed’s anticipated milestones for the remainder of 2026 and early 2027 include:

• DLB: CervoMed will continue its efforts to advance the development of neflamapimod as a treatment for DLB, including the Company’s primary strategic objective to establish a partnership to advance neflamapimod into a Phase 3 clinical trial in patients with DLB, as well as its continued evaluation of alternatives to finance the program.
  
  
• FTD: CervoMed expects to report 24-week biomarker data from its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA at CTAD 2026 in mid-November 2026. The Company expects to report initial 24-week clinical data, as well as additional biomarker data, at the Alzheimer’s & Parkinson’s Diseases Conference in March 2027, and full topline data from the trial in the second quarter of 2027.
  
  
• ALS: CervoMed expects dosing of the first patient with neflamapimod in the EXPERTS-ALS trial, which will evaluate neflamapimod for the treatment of ALS, in the first quarter of 2027.
  
  
• RAS: CervoMed expects to obtain topline data from its Phase 2a RESTORE trial evaluating neflamapimod in patients recovering from acute ischemic stroke by the end of 2026.
  
  

Third Quarter 2026 Financial Results

Cash Position: As of September 30, 2026, CervoMed had approximately $19.6 million in cash, cash equivalents, and marketable securities, as compared to $20.9 million as of December 31, 2025. Based on its current operating plan, CervoMed believes its cash, cash equivalents, and marketable securities on hand as of September 30, 2026, will enable the Company to fund its planned operating expenses and capital expenditure requirements through the third quarter of 2027.

Grant Revenue: There was no grant revenue recognized for the three months ended September 30, 2026, compared to approximately $0.3 million for the same period in 2025. The decrease was due to the completion of CervoMed’s Phase 2b RewinD-LB trial in mid-2025 and, accordingly, there currently being no further funding available or expected under the $21.3 million grant previously awarded to CervoMed by the National Institute on Aging to support the trial.

Research and Development (R&D) Expenses: R&D expenses for the three months ended September 30, 2026, were approximately $3.7 million, compared to approximately $6.0 million for the same period in 2025. The decrease was primarily due to lower costs related to the Company’s completed RewinD-LB Trial, decreases in personnel costs, costs related to the CervoMed’s ongoing Restore Trial in RAS, and other lower R&D costs. These decreases were partially offset by increases in costs related to the Company’s ongoing Phase 2a clinical trial in nfvPPA and other clinical and nonclinical costs.

General and Administrative (G&A) Expenses: G&A expenses were approximately $2.4 million during the three months ended September 30, 2026, compared to approximately $2.3 million for the same period in 2025. The increase was primarily due to increases in personnel costs, stock-based compensation expense, and professional fees, the latter driven by added legal expenses for patent work, other corporate legal expenses, and consulting expenses. The increase was partially offset by lower costs associated with insurance, taxes, and similar fees.

Net Loss: Net loss was approximately $5.9 million for the three months ended September 30, 2026, compared to approximately $7.7 million for the same period in 2025. The decrease was primarily due to lower total operating expenses, partially offset by a decrease in grant revenue.

About Neflamapimod
Neflamapimod is an investigational, orally administered small-molecule drug that readily crosses the blood-brain barrier and selectively inhibits the alpha isoform of p38 MAP kinase, a key driver of neuroinflammation and synaptic dysfunction. By targeting the critical disease processes underlying degenerative disorders of the brain, neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of DLB, recovery after ischemic stroke, and primary progressive aphasia.

In nonclinical studies, neflamapimod restored synaptic function within the basal forebrain cholinergic system, the brain region most affected in DLB. Across Phase 1 and 2 clinical trials involving more than 800 participants, the drug has been generally well tolerated and demonstrated consistent signals of efficacy. In the 91-patient Phase 2a AscenD-LB trial, neflamapimod significantly improved dementia severity and functional mobility in patients with DLB. Results from the 159-patient Phase 2b RewinD-LB trial, a 16-week randomized, double-blind, placebo-controlled trial followed by a 32-week neflamapimod-only extension, further supported neflamapimod’s potential to deliver meaningful clinical benefit, improving both cognitive and functional outcomes and showing positive effects on key markers of neurodegeneration, one by structural MRI and one a blood-based biomarker. Across both studies, the greatest benefits were observed in patients without Alzheimer’s disease (AD) co-pathology. Collectively, these findings underscore the therapeutic promise and scientific validity of neflamapimod as a potential treatment for DLB and other degenerative brain disorders.

About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s Phase 2b RewinD-LB clinical trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology. In November 2025, CervoMed announced alignment with the FDA on a potential registration path for neflamapimod in DLB, and the Company is currently focused on identifying a strategic partner to advance neflamapimod into a Phase 3 trial in DLB. CervoMed reported initial 12-week biomarker data from its ongoing Phase 2a clinical trial in nfvPPA in October 2026 and expects to present 24-week biomarker data at CTAD 2026 in mid-November 2026. The Company also expects dosing of the first patient with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the first quarter of 2027.

Forward-Looking Statements
This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations, or forecasts for the future of the Company, including, but not limited to: the Company’s need to acquire sufficient funding, including funding (through a strategic partnership or otherwise) for any future trial in patients with DLB, and its ability to continue as a going concern; the Company’s plan to focus on strategic partnering to advance neflamapimod into Phase 3 for DLB and the timing of entering into any such partnership, if at all; the therapeutic potential of neflamapimod in DLB, nfvPPA, ALS, or any other indication, including the degree of sustainability of any therapeutic effects, its potential impact on the rate of disease progression and/or clinical worsening, the optimal dosing regimen to achieve therapeutic effects, or any other treatment effects observed in any clinical trial on any clinical, biomarker, or other outcome measure; the anticipated timing and achievement of clinical and development milestones, including the Company’s initiation of any Phase 3 trial in patients with DLB or the impact, if any, of the Innovation Passport Designation on any future regulatory milestone or the timing thereof; the anticipated data readouts from the Company’s Phase 2a trial in nfvPPA and the anticipated dosing of the first patient with neflamapimod in the EXPERTS-ALS trial; and any other expected or implied benefits, results, or expectations, including the extent (if any) to which neflamapimod may demonstrate efficacy or other clinical or biomarker improvements in patients with DLB or in any other indication. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “aims,” “seeks,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential,” “target,” “project,” “contemplate,” “predict,” “forecast,” “continue,” or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company’s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company’s available cash resources, the availability of additional funds on acceptable terms or at all, and the Company’s ability to continue as a going concern; the results of the Company’s clinical trials; the Company’s ability to successfully enter into a partnership to advance neflamapimod into Phase 3 for DLB in a timely manner, on acceptable terms, or at all; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA or other regulators; the Company’s ability to maintain the intellectual property protection afforded by the Company’s patent portfolio; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the US Securities and Exchange Commission (SEC) on March 13, 2026, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.

Contacts

Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431

Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were CervoMed’s third-quarter 2026 financial results?

CervoMed reported a net loss of approximately $5.9 million, compared with approximately $7.7 million in third-quarter 2025. R&D expenses declined to approximately $3.7 million from approximately $6.0 million, while G&A expenses rose to approximately $2.4 million from approximately $2.3 million. No grant revenue was recognized.

When does CervoMed expect its next neflamapimod trial results?

CervoMed expects 24-week aphasia biomarker data in mid-November 2026 and RESTORE stroke-trial topline data by the end of 2026. Initial 24-week aphasia clinical data and additional biomarker data are expected in March 2027, followed by full topline data in the second quarter of 2027.

Why does CervoMed plan to use 100mg twice-daily neflamapimod dosing?

CervoMed believes 100mg twice daily is the optimal regimen and expects it to achieve target trough plasma drug concentrations in nearly all patients. A 50mg oral tablet formulation will be used in future studies, and the FDA has removed the prior drug exposure limit for future clinical trials.